Skip to content 
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified. more
| Time Frame | PBE | S&P500 |
|---|---|---|
| 1-Week Return | 2.3% | -0.22% |
| 1-Month Return | -0.24% | -0.62% |
| 3-Month Return | 12.3% | 1.88% |
| 6-Month Return | 23.94% | 15.23% |
| 1-Year Return | 33.81% | 15.12% |
| 3-Year Return | 62.78% | 71.32% |
| 5-Year Return | 24.79% | 75.07% |
| 10-Year Return | 124.12% | 257.76% |
| Stock name | Ticker | Weight |
|---|---|---|
 Illumina Inc | ILMN | 5.62% |
 Natera Inc | NTRA | 5.61% |
 Gilead Sciences Inc | GILD | 5.23% |
 Biogen Inc | BIIB | 5.11% |
 Royalty Pharma PLC | RPRX | 4.89% |
 Regeneron Pharmaceuticals Inc | REGN | 4.88% |
 Vertex Pharmaceuticals Inc | VRTX | 4.81% |
 Amgen Inc | AMGN | 4.43% |
 Sarepta Therapeutics Inc | SRPT | 3.07% |
 Novavax Inc | NVAX | 2.98% |
 Exelixis Inc | EXEL | 2.9% |
 TG Therapeutics Inc | TGTX | 2.86% |
 QIAGEN NV | QGEN | 2.86% |
 Halozyme Therapeutics Inc | HALO | 2.82% |
 Moderna Inc | MRNA | 2.8% |
 Neurocrine Biosciences Inc | NBIX | 2.78% |
 BioMarin Pharmaceutical Inc | BMRN | 2.77% |
 Incyte Corp | INCY | 2.77% |
 Repligen Corp | RGEN | 2.76% |
 United Therapeutics Corp | UTHR | 2.7% |
 Protagonist Therapeutics Inc | PTGX | 2.68% |
 AnaptysBio Inc | ANAB | 2.65% |
 Vericel Corp | VCEL | 2.6% |
 PTC Therapeutics Inc | PTCT | 2.6% |
 Veracyte Inc | VCYT | 2.59% |
 ACADIA Pharmaceuticals Inc | ACAD | 2.52% |
 Ardelyx Inc | ARDX | 2.51% |
 BioCryst Pharmaceuticals Inc | BCRX | 2.49% |
 Legend Biotech Corp | LEGN | 2.32% |
 Collegium Pharmaceutical Inc | COLL | 2.29% |
 Invesco Government & Agency Portfolio | AGPXX | 0.06% |
 USD Pending Dividends | USD.Pending.Dividends | 0.03% |
 CASH & EQUIVALENTS | CASH...EQUIVALENTS | 0% |
 SECURITIES LENDING - BNYM | SECURITIES.LENDING...BNYM | 0% |
| Sector | Weight |
|---|---|
|
Health care | 100.00% |
Invesco Dynamic Biotechnology & Genome ETF (PBE) share price today is $94.91.
Yes, Indians can buy shares of Invesco Dynamic Biotechnology & Genome ETF (PBE) on Vested. To buy PBE from India, you can open a US Brokerage account by signing up on Vested. The account opening process is completely digital and secure, and takes 3-5 minutes to complete.
Yes, you can purchase fractional shares of Invesco Dynamic Biotechnology & Genome ETF (PBE) on Vested. You can start investing in Invesco Dynamic Biotechnology & Genome ETF (PBE) with a minimum investment of $1.
The 52-week high price of Invesco Dynamic Biotechnology & Genome ETF (PBE) is $98.82. The 52-week low price of Invesco Dynamic Biotechnology & Genome ETF (PBE) is $66.63.
The stock symbol (or ticker) of Invesco Dynamic Biotechnology & Genome ETF is PBE.
Yes, you can setup SIP in Invesco Dynamic Biotechnology & Genome ETF shares. Follow the below steps to create the SIP:
Here is the historical performance of PBE on the Vested app.
The expense ratio of Invesco Dynamic Biotechnology & Genome ETF (PBE) is 0.58%.
Link copied 
